Naccarelli Gerald V
Heart and Vascular Institute, Penn State University College of Medicine, Hershey, PA, USA.
J Interv Card Electrophysiol. 2011 Jun;31(1):55-60. doi: 10.1007/s10840-011-9550-8. Epub 2011 Feb 19.
Dronedarone, an amiodarone analog, was developed to be a safer alternative to amiodarone. Dronedarone is useful in suppressing atrial fibrillation/flutter and controlling the ventricular response. Dronedarone reduced cardiovascular hospitalization in the ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter). This paper reviews the results of ATHENA, including subsequent sub-analyses of the trial. These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of dronedarone. Future studies will clarify the mechanisms of this beneficial effect.
决奈达隆是一种胺碘酮类似物，被开发为比胺碘酮更安全的替代品。决奈达隆可有效抑制心房颤动/心房扑动并控制心室反应。在ATHENA试验（一项安慰剂对照、双盲、平行组试验，旨在评估每日两次服用400 mg决奈达隆对预防心房颤动/心房扑动患者因任何原因导致的心血管住院或死亡的疗效）中，决奈达隆减少了心血管住院率。本文回顾了ATHENA试验的结果，包括该试验随后的亚组分析。这些结果提出了一个假设，即该试验中观察到的许多益处可能不仅仅归因于决奈达隆的抗心律失常特性。未来的研究将阐明这种有益作用的机制。
